title: Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP.
abstract: Survivin is an inhibitor of apoptosis whose expression may be associated with inferior outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab. Caspase-3 is the final caspase of the apoptotic cascade and its pattern of expression may also be related to patients' outcome. In this study we investigated immunohistochemical expression of survivin and caspase-3 (CPP32) in 57 patients with DLBCL treated with rituximab and CHOP (R-CHOP). According to previously published criteria, we separately analyzed correlation of different types of survivin expression with patients' outcome. Nuclear survivin was expressed in only 26% of cases, cytoplasmic survivin was expressed in 81% of cases while application of immunoreactivity scoring system yielded 58% of survivin positive cases. Caspase-3 was expressed in 77% of cases. There were no significant correlations between any type of survivin expression and response to treatment or survival of the patients. The expression of caspase-3 was also not associated with patients' outcome. We conclude that survivin and caspase-3 have no significant prognostic significance in patients with DLBCL treated with R-CHOP.
authors.affiliation: Division of Hematology and Department of Medicine, University Hospital Center Zagreb and School of Medicine University of Zagreb, Kispaticeva 12, 10 000 Zagreb, Croatia. mitrovic@mef.hr
authors.forename: Zdravko
authors.initials: Z
authors.lastname: Mitrović
authors.forename: Ivana
authors.initials: I
authors.lastname: Ilić
authors.forename: Igor
authors.initials: I
authors.lastname: Aurer
authors.forename: Sandra Bašić
authors.initials: SB
authors.lastname: Kinda
authors.forename: Ivo
authors.initials: I
authors.lastname: Radman
authors.forename: Snježana
authors.initials: S
authors.lastname: Dotlić
authors.forename: Radmila
authors.initials: R
authors.lastname: Ajduković
authors.forename: Boris
authors.initials: B
authors.lastname: Labar
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D053148:Caspase 3 / Q000096:biosynthesis*; D003520:Cyclophosphamide; D004317:Doxorubicin; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000096:biosynthesis*; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone; D011379:Prognosis; D000069283:Rituximab; D000077022:Survivin; D014750:Vincristine; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C505407:CASP3 protein, human; D053148:Caspase 3; D011241:Prednisone